NeOnc Faces Mounting Losses Amidst Clinical Trial Progress

TL;DR

**NTHI is a high-burn biotech with promising but unproven drugs, making it a speculative bet for aggressive investors only.**

AI Summary

NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies, including glioblastoma and meningioma. The company reported minimal revenue of $39,990 from January 1, 2023, to September 30, 2025, and does not anticipate significant revenues in the foreseeable future. NTHI experienced substantial net losses, with $14,921,065 in 2023, $11,898,464 in 2024, and a significant increase to $46,622,106 for the nine months ended September 30, 2025, compared to $9,645,482 for the same period in 2024. The accumulated deficit reached $50,608,445 by December 31, 2024, and $97,230,551 by September 30, 2025. NTHI's lead product, NEO100, a purified form of perillyl acid, is in Phase IIa trials for recurrent malignant glioma and skull-based meningioma, with a projected readout by the end of 2024. The company expanded the NEO100 trial to include Grade III IDH1,2 mutant astrocytomas in June 2023, identifying approximately 80 additional candidates. Its second lead product, NEO212, a combination of temozolomide and perillyl alcohol, received IND approval and began a Phase I/II oral trial in Q4 2023 for primary and secondary brain tumors. NTHI is offering 111,732 shares of common stock through selling stockholders, with no proceeds going to the company.

Why It Matters

This S-1 filing reveals NeOnc Technologies Holdings, Inc.'s precarious financial state, with an accumulated deficit of $97.2 million by September 30, 2025, and minimal revenue, signaling high risk for investors. While the company is advancing two lead drug candidates, NEO100 and NEO212, into Phase II and Phase I/II trials respectively for aggressive brain cancers, the lack of product sales and significant losses underscore the long, costly path to market. The expansion of NEO100's trial population to include Grade III IDH1,2 mutant astrocytomas could expedite results, but NTHI operates in a highly competitive biopharmaceutical landscape where clinical trial failures are common and regulatory approval is uncertain. Employees and customers face the inherent risks of a clinical-stage company with no approved products.

Risk Assessment

Risk Level: high — NTHI exhibits a high risk level due to its substantial and increasing net losses, reaching $46,622,106 for the nine months ended September 30, 2025, and an accumulated deficit of $97,230,551. The company has generated only $39,990 in revenue from January 1, 2023, to September 30, 2025, and explicitly states it does not anticipate significant revenues for the foreseeable future, indicating a reliance on external financing and a lack of sustainable operations.

Analyst Insight

Investors should approach NTHI with extreme caution, recognizing it as a highly speculative investment in a clinical-stage biopharmaceutical company. Given the significant accumulated deficit of $97.2 million and minimal revenue, only investors with a high-risk tolerance and a long-term horizon should consider NTHI, understanding that substantial dilution or even bankruptcy remains a possibility without successful clinical trials and subsequent commercialization.

Financial Highlights

debt To Equity

N/A

revenue

$39,990

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$97,230,551

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $39,990 — Total Revenue (Generated from January 1, 2023, to September 30, 2025, indicating minimal commercial activity.)
• $14,921,065 — Net Loss for 2023 (Reflects significant operational expenses without corresponding revenue.)
• $11,898,464 — Net Loss for 2024 (Continued substantial losses, though slightly lower than 2023.)
• $46,622,106 — Net Loss for 9 months ended Sep 30, 2025 (A sharp increase in losses compared to the prior year, indicating accelerated burn rate.)
• $9,645,482 — Net Loss for 9 months ended Sep 30, 2024 (Baseline for comparison to the significantly higher 2025 loss.)
• $97,230,551 — Accumulated Deficit as of Sep 30, 2025 (Highlights the company's substantial historical losses and negative equity.)
• 111,732 — Shares Offered by Selling Stockholders (Represents the number of common stock shares being offered, with no proceeds to the company.)
• $8.96 — Last Reported Sale Price per Share (On December 9, 2025, on The Nasdaq Global Market.)
• 2024 — Projected Readout for NEO100 Phase II Studies (Advanced by a full year from the original 2025 timeline due to expanded patient population.)
• 80 — Identified Grade III IDH1,2 mutation-positive candidates (Additional patients targeted for NEO100 Phase IIa study, expanding the enrollment pool.)

Key Players & Entities

• NeOnc Technologies Holdings, Inc. (company) — Registrant and parent company
• NeOnc Technologies, Inc. (company) — Wholly-owned subsidiary
• Amir Farrokh Heshmatpour (person) — Chief Executive Officer
• Thomas J. Poletti, Esq. (person) — Legal counsel from Manatt, Phelps & Phillips LLP
• Veronica Lah, Esq. (person) — Legal counsel from Manatt, Phelps & Phillips LLP
• Dr. Thomas Chen (person) — Contact person for the company
• Keithly Garnett (person) — Contact person for the company
• Securities and Exchange Commission (regulator) — Regulatory body for S-1 filing
• Food and Drug Administration (regulator) — Regulatory body for drug approvals
• The Nasdaq Global Market (company) — Stock exchange where NTHI common stock is listed

FAQ

Risk Factors

• Substantial Accumulated Deficit [high — financial]: The company has a significant accumulated deficit of $97,230,551 as of September 30, 2025, indicating a history of substantial losses and negative equity. This raises concerns about long-term financial viability without significant future funding.
• Increasing Net Losses [high — financial]: Net losses have shown a sharp increase, with $46,622,106 for the nine months ended September 30, 2025, compared to $9,645,482 for the same period in 2024. This accelerated burn rate suggests increasing operational costs without commensurate revenue growth.
• Clinical Trial Dependence [high — operational]: The company's success is heavily reliant on the successful development and regulatory approval of its lead product candidates, NEO100 and NEO212. Delays or failures in clinical trials (Phase IIa for NEO100, Phase I/II for NEO212) could severely impact future prospects.
• Product Approval Uncertainty [high — regulatory]: As a clinical-stage biopharmaceutical company, NTHI faces significant regulatory hurdles for its drug candidates. The timeline for potential approval and market entry for NEO100 and NEO212 is uncertain and subject to rigorous FDA review.
• No Proceeds to Company from Offering [medium — financial]: The current offering involves selling stockholders selling 111,732 shares, with no proceeds going to the company. This means the company will not receive capital from this transaction to fund its operations or development efforts.
• Limited Revenue and Future Prospects [high — market]: The company reported minimal revenue of $39,990 for the period ending September 30, 2025, and does not anticipate significant revenues in the foreseeable future. This lack of commercial traction poses a significant risk.

Industry Context

The biopharmaceutical industry, particularly in oncology, is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like NTHI focus on niche areas such as rare or aggressive brain cancers, where unmet medical needs are high. The competitive landscape involves both large pharmaceutical companies and smaller biotech firms, with success often hinging on novel drug discovery, robust clinical trial data, and effective intellectual property management.

Regulatory Implications

As a clinical-stage biopharmaceutical company, NTHI is subject to stringent regulatory oversight by bodies like the FDA. The success of its drug candidates, NEO100 and NEO212, is contingent upon successful completion of clinical trials and subsequent regulatory approval. Any delays, adverse findings, or failure to meet regulatory standards could significantly impede or halt development.

What Investors Should Do

1. Monitor clinical trial results closely.
2. Assess the company's cash burn rate and future funding needs.
3. Consider the lack of proceeds to the company in the current offering.
4. Evaluate the competitive landscape and market potential for brain cancer treatments.

Key Dates

• 2024-12-31: Projected Readout for NEO100 Phase II Studies — This is a critical milestone for the company, as positive results could validate the efficacy of their lead drug candidate and pave the way for further development and potential commercialization.
• 2023-10-01: Q4 2023 - Phase I/II oral trial for NEO212 began — Initiation of a clinical trial for NEO212 marks progress in the company's pipeline, aiming to address primary and secondary brain tumors.
• 2023-06-01: Expanded NEO100 trial to include Grade III IDH1,2 mutant astrocytomas — This expansion broadens the patient population for NEO100's Phase IIa trial, potentially accelerating enrollment and providing more comprehensive data.

Glossary

Intracranial Malignancies

Cancers that originate in or spread to the brain or central nervous system. (This is the primary focus of NTHI's drug development efforts, specifically glioblastoma and meningioma.)

Glioblastoma

A fast-growing, aggressive type of brain tumor. (NTHI's lead product, NEO100, is being developed for this indication, representing a significant unmet medical need.)

Meningioma

A tumor that arises from the membranes that surround the brain and spinal cord. (NTHI is also developing NEO100 for skull-based meningioma, another type of brain tumor.)

Perillyl Acid (POH)

A naturally occurring monoterpene found in plants like lavender and peppermint, being developed by NTHI as NEO100. (This is the active pharmaceutical ingredient in NTHI's lead drug candidate, NEO100.)

Temozolomide (TMZ)

A chemotherapy drug commonly used to treat brain tumors. (This is one of the components of NTHI's second lead product candidate, NEO212.)

IND Approval

Investigational New Drug application approval from the FDA, allowing for clinical trials in humans. (NTHI received IND approval for NEO212, signifying a key step in its development pathway.)

Phase IIa Trial

A clinical trial phase designed to assess the efficacy and safety of a drug in a small group of patients with the target disease. (NEO100 is currently in Phase IIa trials, a crucial stage for demonstrating therapeutic potential.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, representing negative retained earnings. (NTHI's substantial accumulated deficit of over $97 million highlights its historical unprofitability and reliance on external funding.)

Year-Over-Year Comparison

The S-1 filing reveals a significant deterioration in NTHI's financial performance compared to prior periods. Most notably, net losses have sharply increased, with the nine months ended September 30, 2025, showing a loss of $46,622,106, a substantial jump from $9,645,482 in the same period of 2024. This indicates an accelerating burn rate. While revenue remains minimal, the growing deficit and increased operational expenses highlight the company's continued reliance on external financing for its clinical development programs.

Key Financial Figures

• $0.0001 — he "Shares") of common stock, par value $0.0001 ("common stock") of NeOnc Technologies
• $8.96 — n stock on The Nasdaq Global Market was $8.96 per share. We are an "emerging growth
• $39,990 — 30, 2025 have only generated revenue of $39,990. We do not anticipate generating signif
• $11,898,464 — foreseeable future. We had net loss of $11,898,464 and $14,921,065 for the years ended Dec
• $14,921,065 — ure. We had net loss of $11,898,464 and $14,921,065 for the years ended December 31, 2024 a
• $50,608,445 — 2024, we had an accumulated deficit of $50,608,445. Our net loss was $46,622,106 and $9,64
• $46,622,106 — eficit of $50,608,445. Our net loss was $46,622,106 and $9,645,482 for the nine months ende
• $9,645,482 — 8,445. Our net loss was $46,622,106 and $9,645,482 for the nine months ended September 30,
• $97,230,551 — ively. We had an accumulated deficit of $97,230,551 at September 30, 2025. Implications of
• $1.235 billion — ing growth company if we have more than $1.235 billion in annual revenue, we have more than $7
• $700 million — on in annual revenue, we have more than $700 million in market value of our stock held by no
• $1 billion — ort on Form 10-K) or we issue more than $1 billion of non-convertible debt securities over

Filing Documents

• neonctechnologies_s1.htm (S-1) — 2304KB
• neonctechnologies_ex5-1.htm (EX-5.1) — 12KB
• neonctechnologies_ex21-1.htm (EX-21.1) — 3KB
• neonctechnologies_ex23-2.htm (EX-23.2) — 3KB
• neonctechnologies_ex107.htm (EX-FILING FEES) — 28KB
• img_001.jpg (GRAPHIC) — 66KB
• img_002.jpg (GRAPHIC) — 79KB
• img_003.jpg (GRAPHIC) — 43KB
• img_004.jpg (GRAPHIC) — 89KB
• img_005.jpg (GRAPHIC) — 126KB
• img_006.jpg (GRAPHIC) — 97KB
• img_007.jpg (GRAPHIC) — 73KB
• img_008.jpg (GRAPHIC) — 75KB
• img_009.jpg (GRAPHIC) — 11KB
• img_010.jpg (GRAPHIC) — 34KB
• img_011.jpg (GRAPHIC) — 27KB
• img_012.jpg (GRAPHIC) — 56KB
• img_013.jpg (GRAPHIC) — 14KB
• img_014.jpg (GRAPHIC) — 34KB
• img_015.jpg (GRAPHIC) — 19KB
• img_016.jpg (GRAPHIC) — 34KB
• img_017.jpg (GRAPHIC) — 42KB
• img_018.jpg (GRAPHIC) — 53KB
• img_019.jpg (GRAPHIC) — 48KB
• img_020.jpg (GRAPHIC) — 42KB
• img_021.jpg (GRAPHIC) — 30KB
• 0001829126-25-009965.txt ( ) — 10993KB
• cik0001979414-20250930.xsd (EX-101.SCH) — 60KB
• cik0001979414-20250930_cal.xml (EX-101.CAL) — 71KB
• cik0001979414-20250930_def.xml (EX-101.DEF) — 360KB
• cik0001979414-20250930_lab.xml (EX-101.LAB) — 352KB
• cik0001979414-20250930_pre.xml (EX-101.PRE) — 417KB
• neonctechnologies_s1_htm.xml (XML) — 972KB
• neonctechnologies_ex107_htm.xml (XML) — 9KB

RISK FACTORS

RISK FACTORS 6 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 7 MARKET AND INDUSTRY DATA 9 TRADEMARKS, SERVICE MARKS AND TRADENAMES 10

USE OF PROCEEDS

USE OF PROCEEDS 11 DIVIDEND POLICY 12 CAPITALIZATION 13

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 14

BUSINESS

BUSINESS 28 MANAGEMENT 80 EXECUTIVE AND DIRECTOR COMPENSATION 87

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 92 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 94

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 99 SHARES ELIGIBLE FOR FUTURE SALE 103 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS 105 DESCRIPTION OF PRIVATE PLACEMENT 109 SELLING STOCKHOLDER 110 PLAN OF DISTRIBUTION 111 LEGAL MATTERS 113 EXPERTS 113 WHERE YOU CAN FIND ADDITIONAL INFORMATION 113 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor the Selling Stockholder have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor the Selling Stockholder take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholder is offering to sell, and seeking offers to buy, shares of their common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date. For investors outside the United States: Neither we nor the Selling Stockholder have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Selling Stockholder and the di

Risk Factors

Risk Factors Investing in our common stock involves a high degree of risk. Before you invest you should carefully consider the risks and uncertainties described below and the other information in this prospectus, and under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which is incorporated by reference, as well as the other information in this prospectus, before deciding whether to invest in shares of our common stock. If any of the following risks actually occurs, our business, results of operations and financial condition could be materially adversely affected. In this case, the trading price of our common stock would likely decline, and you might lose part or all your investment in our common stock. Additional risks not currently known to us or which we consider immaterial based on information currently available to us may also materially adversely affect us. 6 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "anticipate," "b

View Full Filing

View this S-1 filing on SEC EDGAR